JP2012517441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517441A5 JP2012517441A5 JP2011549315A JP2011549315A JP2012517441A5 JP 2012517441 A5 JP2012517441 A5 JP 2012517441A5 JP 2011549315 A JP2011549315 A JP 2011549315A JP 2011549315 A JP2011549315 A JP 2011549315A JP 2012517441 A5 JP2012517441 A5 JP 2012517441A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- pharmaceutical composition
- alkyl
- hydrogen atom
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 27
- -1 3-ethoxy-4-methoxyphenyl Chemical group 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 15
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 239000000814 tuberculostatic agent Substances 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 201000008827 tuberculosis Diseases 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229960003350 isoniazid Drugs 0.000 claims 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- 229960001225 rifampicin Drugs 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 claims 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 claims 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 108010065839 Capreomycin Proteins 0.000 claims 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 claims 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- 229960004909 aminosalicylic acid Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 229940053013 bio-mycin Drugs 0.000 claims 1
- 229960004602 capreomycin Drugs 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical group OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
- 229960003077 cycloserine Drugs 0.000 claims 1
- 229960000285 ethambutol Drugs 0.000 claims 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006277 halobenzyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960003907 linezolid Drugs 0.000 claims 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims 1
- NTIBXLBUWCCEBH-UHFFFAOYSA-N methyl 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoate Chemical group C1C2=CC=CC=C2C(=O)N1C(CC(=O)OC)C1=CC=C(OC)C(OC)=C1 NTIBXLBUWCCEBH-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- IMOZEMNVLZVGJZ-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical group C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 229960000918 protionamide Drugs 0.000 claims 1
- 229960005206 pyrazinamide Drugs 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- 229960000885 rifabutin Drugs 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 claims 1
- 229960003231 thioacetazone Drugs 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 0 C*c1cc(CCN)ccc1* Chemical compound C*c1cc(CCN)ccc1* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15146709P | 2009-02-10 | 2009-02-10 | |
| US61/151,467 | 2009-02-10 | ||
| PCT/US2010/023533 WO2010093588A1 (en) | 2009-02-10 | 2010-02-09 | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015081559A Division JP2015164928A (ja) | 2009-02-10 | 2015-04-13 | 結核の治療、予防及び管理のためのｐｄｅ４モジュレーターの使用法及び含有組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012517441A JP2012517441A (ja) | 2012-08-02 |
| JP2012517441A5 true JP2012517441A5 (enExample) | 2013-03-28 |
Family
ID=42077260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549315A Pending JP2012517441A (ja) | 2009-02-10 | 2010-02-09 | 結核の治療、予防及び管理のためのｐｄｅ４モジュレーターの使用法及び含有組成物 |
| JP2015081559A Pending JP2015164928A (ja) | 2009-02-10 | 2015-04-13 | 結核の治療、予防及び管理のためのｐｄｅ４モジュレーターの使用法及び含有組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015081559A Pending JP2015164928A (ja) | 2009-02-10 | 2015-04-13 | 結核の治療、予防及び管理のためのｐｄｅ４モジュレーターの使用法及び含有組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20120149716A1 (enExample) |
| EP (2) | EP2395995A1 (enExample) |
| JP (2) | JP2012517441A (enExample) |
| KR (1) | KR20110116049A (enExample) |
| CN (1) | CN102387798A (enExample) |
| AP (1) | AP3437A (enExample) |
| AU (1) | AU2010213936B2 (enExample) |
| BR (1) | BRPI1007500A2 (enExample) |
| CA (1) | CA2750123A1 (enExample) |
| CO (1) | CO6410289A2 (enExample) |
| CR (1) | CR20110411A (enExample) |
| EA (1) | EA201171035A1 (enExample) |
| EC (1) | ECSP11011295A (enExample) |
| HK (1) | HK1205681A1 (enExample) |
| IL (1) | IL214176A (enExample) |
| MX (1) | MX2011008132A (enExample) |
| MY (1) | MY160002A (enExample) |
| NI (1) | NI201100154A (enExample) |
| NZ (1) | NZ594193A (enExample) |
| PE (2) | PE20151143A1 (enExample) |
| SG (2) | SG10201402158VA (enExample) |
| UA (1) | UA103791C2 (enExample) |
| WO (1) | WO2010093588A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6143675B2 (ja) | 2010-12-16 | 2017-06-07 | セルジーン コーポレイション | 難溶性薬物の制御放出経口剤形及びその使用 |
| PH12014500593A1 (en) | 2011-09-14 | 2019-09-02 | Celgene Corp | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
| SG10201605251VA (en) | 2011-12-27 | 2016-08-30 | Celgene Corp | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione |
| WO2013119607A2 (en) * | 2012-02-08 | 2013-08-15 | Celgene Corporation | Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
| DE102018201827A1 (de) * | 2017-02-28 | 2018-08-30 | Aktiebolaget Skf | Wälzlager |
| CN112220785B (zh) * | 2020-09-22 | 2021-12-31 | 北京鑫开元医药科技有限公司 | 一种pde4抑制剂药物组合物及其制备方法与用途 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| IT1276040B1 (it) * | 1993-07-27 | 1997-10-24 | Angelini Francesco Ist Ricerca | Uso della benzidamina nel trattamento di stati patologici causati dal tnf |
| EP0749428B1 (en) * | 1994-03-09 | 1998-07-29 | Pfizer Inc. | Isoxazoline compounds as inhibitors of tnf release |
| US5610198A (en) * | 1994-03-18 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| US6518281B2 (en) | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| AU729247B2 (en) | 1996-08-12 | 2001-01-25 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| JP2001511448A (ja) | 1997-07-31 | 2001-08-14 | セルジーン コーポレイション | 置換アルカノヒドロキサム酸およびＴＮＦαレベルの減少方法 |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| CN1388758A (zh) * | 2000-08-09 | 2003-01-01 | 灵药生物技术有限公司 | 抗结核病药物的新颖的药学组合物及其制备方法 |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| WO2003080048A1 (en) | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| WO2004043378A2 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| CA2506442A1 (en) | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| ATE449081T1 (de) | 2002-12-30 | 2009-12-15 | Celgene Corp | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen |
| MXPA05009434A (es) | 2003-03-05 | 2005-11-23 | Celgene Corp | Compuestos de difeniletileno y usos de los mismos. |
| MXPA05009595A (es) | 2003-03-12 | 2005-11-04 | Celgene Corp | Compuestos 7-amino-isoindolilo y sus usos farmaceuticos. |
| ES2362484T3 (es) | 2003-03-12 | 2011-07-06 | Celgene Corporation | Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos. |
| US7244259B2 (en) | 2003-10-31 | 2007-07-17 | Ethicon, Inc. | Guide for surgical device for the treatment of urinary incontinence |
| US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| BRPI0519030A2 (pt) * | 2004-12-13 | 2008-12-23 | Celgene Corp | mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
-
2010
- 2010-02-09 AU AU2010213936A patent/AU2010213936B2/en not_active Ceased
- 2010-02-09 CN CN2010800159215A patent/CN102387798A/zh active Pending
- 2010-02-09 CA CA2750123A patent/CA2750123A1/en not_active Abandoned
- 2010-02-09 EP EP10704460A patent/EP2395995A1/en not_active Withdrawn
- 2010-02-09 UA UAA201110844A patent/UA103791C2/uk unknown
- 2010-02-09 NZ NZ594193A patent/NZ594193A/xx not_active IP Right Cessation
- 2010-02-09 WO PCT/US2010/023533 patent/WO2010093588A1/en not_active Ceased
- 2010-02-09 KR KR1020117021146A patent/KR20110116049A/ko not_active Ceased
- 2010-02-09 EA EA201171035A patent/EA201171035A1/ru unknown
- 2010-02-09 JP JP2011549315A patent/JP2012517441A/ja active Pending
- 2010-02-09 BR BRPI1007500A patent/BRPI1007500A2/pt not_active IP Right Cessation
- 2010-02-09 EP EP14170043.5A patent/EP2818164A1/en not_active Withdrawn
- 2010-02-09 PE PE2015000636A patent/PE20151143A1/es not_active Application Discontinuation
- 2010-02-09 SG SG10201402158VA patent/SG10201402158VA/en unknown
- 2010-02-09 AP AP2011005849A patent/AP3437A/xx active
- 2010-02-09 MX MX2011008132A patent/MX2011008132A/es active IP Right Grant
- 2010-02-09 PE PE2011001445A patent/PE20120580A1/es not_active Application Discontinuation
- 2010-02-09 US US13/148,659 patent/US20120149716A1/en not_active Abandoned
- 2010-02-09 MY MYPI2011003673A patent/MY160002A/en unknown
- 2010-02-09 SG SG2011054129A patent/SG173149A1/en unknown
-
2011
- 2011-07-19 IL IL214176A patent/IL214176A/en not_active IP Right Cessation
- 2011-07-29 CR CR20110411A patent/CR20110411A/es unknown
- 2011-08-09 NI NI201100154A patent/NI201100154A/es unknown
- 2011-08-21 EC EC2011011295A patent/ECSP11011295A/es unknown
- 2011-09-09 CO CO11116668A patent/CO6410289A2/es not_active Application Discontinuation
-
2015
- 2015-04-13 JP JP2015081559A patent/JP2015164928A/ja active Pending
- 2015-06-30 HK HK15106201.5A patent/HK1205681A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517441A5 (enExample) | ||
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| JP6250671B2 (ja) | 免疫関連及び炎症性疾患の治療 | |
| JP2014526500A5 (enExample) | ||
| JP2012502017A5 (enExample) | ||
| JP2009102423A5 (enExample) | ||
| JP2013531070A5 (enExample) | ||
| JP2012515787A5 (enExample) | ||
| JP2017528487A5 (enExample) | ||
| JP2009522289A5 (enExample) | ||
| JP2018511626A5 (enExample) | ||
| JP2008500992A5 (enExample) | ||
| JP2005538099A5 (enExample) | ||
| JP2009507896A5 (enExample) | ||
| RU2012139828A (ru) | Производные пиразолопиперидина в качестве ингибиторов nadph-оксидазы | |
| JP2013521288A5 (enExample) | ||
| JP2018515525A5 (enExample) | ||
| JP7025022B2 (ja) | 骨髄系由来抑制細胞関連障害の治療のための方法 | |
| JP2004526699A5 (enExample) | ||
| JP2018512403A5 (enExample) | ||
| JP2012515788A5 (enExample) | ||
| CN102387798A (zh) | 供治疗、预防和控制结核病的pde4调节剂的使用方法及包含其的组合物 | |
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| JP2013544811A5 (enExample) | ||
| JP2013523817A5 (enExample) |